McHarg A - Search Results

1

Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors.

Napier C, Stewart M, Melrose H, Hopkins B, McHarg A, Wallis R. Napier C, et al. Among authors: mcharg a. Eur J Pharmacol. 1999 Mar 5;368(2-3):259-68. doi: 10.1016/s0014-2999(99)00026-6. Eur J Pharmacol. 1999. PMID: 10193663

2

Characterisation of the contractile activity of eletriptan at the canine vascular 5-HT1B receptor.

Gupta P, Scatchard J, Napier C, McHarg A, Wallis R. Gupta P, et al. Among authors: mcharg a. Eur J Pharmacol. 1999 Feb 19;367(2-3):283-90. doi: 10.1016/s0014-2999(98)00926-1. Eur J Pharmacol. 1999. PMID: 10079003

3

The in vivo pharmacological profile of eletriptan (UK-116,044): a potent and novel 5-HT(1B/1D) receptor agonist.

Gupta P, Butler P, Shepperson NB, McHarg A. Gupta P, et al. Among authors: mcharg a. Eur J Pharmacol. 2000 Jun 9;398(1):73-81. doi: 10.1016/s0014-2999(00)00240-5. Eur J Pharmacol. 2000. PMID: 10856450

4

Serotonergic effects and extracellular brain levels of eletriptan, zolmitriptan and sumatriptan in rat brain.

Johnson DE, Rollema H, Schmidt AW, McHarg AD. Johnson DE, et al. Among authors: mcharg ad. Eur J Pharmacol. 2001 Aug 17;425(3):203-10. doi: 10.1016/s0014-2999(01)01151-7. Eur J Pharmacol. 2001. PMID: 11513839

5

Impact of study design on proarrhythmia prediction in the SCREENIT rabbit isolated heart model.

Steidl-Nichols JV, Hanton G, Leaney J, Liu RC, Leishman D, McHarg A, Wallis R. Steidl-Nichols JV, et al. Among authors: mcharg a. J Pharmacol Toxicol Methods. 2008 Jan-Feb;57(1):9-22. doi: 10.1016/j.vascn.2007.06.003. Epub 2007 Jul 3. J Pharmacol Toxicol Methods. 2008. PMID: 17707659

6

Pharmacology and efficacy of eletriptan for the treatment of migraine attacks.

Diener HC, McHarg A. Diener HC, et al. Among authors: mcharg a. Int J Clin Pract. 2000 Dec;54(10):670-4. Int J Clin Pract. 2000. PMID: 11221281

7

Sunitinib, a receptor tyrosine kinase inhibitor, increases blood pressure in rats without associated changes in cardiac structure and function.

Blasi E, Heyen J, Patyna S, Hemkens M, Ramirez D, John-Baptiste A, Steidl-Nichols J, McHarg A. Blasi E, et al. Among authors: mcharg a. Cardiovasc Ther. 2012 Oct;30(5):287-94. doi: 10.1111/j.1755-5922.2011.00278.x. Epub 2011 May 31. Cardiovasc Ther. 2012. PMID: 21884012 Free article.

8

Cardiovascular differentiation of imatinib and bosutinib in the rat.

Heyen JR, Hu W, Jamieson J, Thibault S, Batugo M, Loi CM, Burns-Naas LA, McHarg AD, Jessen B. Heyen JR, et al. Among authors: mcharg ad. Int J Hematol. 2013 Nov;98(5):597-607. doi: 10.1007/s12185-013-1453-2. Epub 2013 Oct 19. Int J Hematol. 2013. PMID: 24142766

9

Effects of chronic PPAR-agonist treatment on cardiac structure and function, blood pressure, and kidney in healthy sprague-dawley rats.

Blasi ER, Heyen J, Hemkens M, McHarg A, Ecelbarger CM, Tiwari S. Blasi ER, et al. Among authors: mcharg a. PPAR Res. 2009;2009:237865. doi: 10.1155/2009/237865. Epub 2009 Jun 11. PPAR Res. 2009. PMID: 19536351 Free PMC article.

10

PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.

Yuan J, Mehta PP, Yin MJ, Sun S, Zou A, Chen J, Rafidi K, Feng Z, Nickel J, Engebretsen J, Hallin J, Blasina A, Zhang E, Nguyen L, Sun M, Vogt PK, McHarg A, Cheng H, Christensen JG, Kan JL, Bagrodia S. Yuan J, et al. Among authors: mcharg a. Mol Cancer Ther. 2011 Nov;10(11):2189-99. doi: 10.1158/1535-7163.MCT-11-0185. Epub 2011 Jul 12. Mol Cancer Ther. 2011. PMID: 21750219

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

26 results

Search Page